Angiogenic imbalances: the obstetric perspective.
Clinical and experimental evidence indicates that angiogenic imbalances may participate in the mechanisms of disease of several pregnancy complications, some of which may be life threatening. This article reviews current evidence in support of this view and the possibility that the fetus may play a central role in these imbalances; it also reviews recent experimental observations that modulation of angiogenic imbalances during pregnancy may have prophylactic and/or therapeutic value.
Department of Obstetrics and Gynecology, William Beaumont Hospital, 3601 West Thirteen Mile Rd., Royal Oak, MI 48073, USA. jimmy.espinoza@beaumont.edu
Jimmy
J
Espinoza
John E
JE
Uckele
Robert A
RA
Starr
David E
DE
Seubert
Andres F
AF
Espinoza
Stanley M
SM
Berry
D005260:Female; D005317:Fetal Growth Retardation / Q000503:physiopathology; D006801:Humans; D006828:Hydatidiform Mole / Q000503:physiopathology; D009389:Neovascularization, Pathologic / Q000503:physiopathology*; D016471:Ovarian Hyperstimulation Syndrome / Q000503:physiopathology; D011225:Pre-Eclampsia / Q000503:physiopathology; D011247:Pregnancy; D011248:Pregnancy Complications / Q000503:physiopathology*; D042461:Vascular Endothelial Growth Factor A / Q000502:physiology
C467484:VEGFA protein, human; D042461:Vascular Endothelial Growth Factor A